Targeting Head and Neck Atopic Dermatitis: Long-Term Outcomes with Tralokinumab

https://is1-ssl.mzstatic.com/image/thumb/Podcasts112/v4/8e/c5/a1/8ec5a12c-b5ea-0917-968d-114148ca47f8/mza_11631062009583709663.jpeg/600x600bb.jpg

DermConsult

ReachMD

45 episodes

1 week ago

There’s a lot dermatology specialists need to consider when ensuring patients have healthy skin. And at a time when clinical research is increasingly defining skin conditions—and the practice of dermatology itself—as “more than skin deep,” turn to DermConsult. In this special series, dermatology specialists share their expert advice on the diagnosis and treatment of a variety of skin conditions. They also explore the latest clinical research and their very own case studies, so you can rest assured you’ll have access to everything you need to know about the body’s largest organ.

Science

Medicine

RSS

All content for DermConsult is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Medicine

Targeting Head and Neck Atopic Dermatitis: Long-Term Outcomes with Tralokinumab

DermConsult

1 month ago

Targeting Head and Neck Atopic Dermatitis: Long-Term Outcomes with Tralokinumab

Guest: Raj Chovatiya, MD, PhD

Head and neck involvement in atopic dermatitis significantly affects patients’ daily lives, often driving greater stigma, discomfort, and disease severity. Given this region’s impact, a post hoc analysis of the ECZTRA 1 and 2 and ECZTEND trials examined tralokinumab and found that this IL-13 inhibitor not only provided sustained reductions in head and neck EASI scores, but patients also reported better Dermatology Life Quality Index scores. Tune in to hear Dr. Raj Chovatiya dive further into the findings and their potential implications for atopic dermatitis care. Dr. Chovatiya is an Associate Professor at the Rosalind Franklin University Chicago Medical School, as well as the Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.